Die Titel-Verbindungen 4a-c sind durch intramolekulare Cyclisierung der Benzyl-octahydrocyclohepta-pyridine 9a, b darstellbar, die ihrerseits durch die Stufenfolge 5 → 9 erhältlich sind。Die Strukturen von 4 werden 1H- 和 13C-spektroskopisch abgesichert。
Synthesis, characterization and electroluminescence properties of new iridium complexes based on cyclic phenylvinylpyridine derivatives: tuning of emission colour and efficiency by structural control
摘要:
本研究合成了一系列磷光环甲基化铱(III)配合物 4-6,这些配合物具有新的双环苯基乙烯基吡啶配体,并对其光物理、电化学和电致发光(EL)特性进行了系统研究。所有双环和三环金属化配合物都可以通过 1H-NMR、元素分析和 X 射线晶体结构分析进行表征。配合物在溶液、固态和聚合物薄膜中的磷光颜色会因配体结构的不同而发生异常变化。使用这些配合物的电致发光装置在 100 cd m-2 时的外部量子效率(EQE)为 1.2-8.1%,在 571-635 nm 波长范围内实现了电致发光颜色调节,与荧光粉的磷光特性类似。对复合物 4a-c 的 X 射线分析表明,立体阻碍的程度随着环烷环尺寸的增加而增加,从而导致苯基基团的变形引起发射的低色度偏移。X 射线分析还表明,长的铱碳键不利于高效电致发光。此外,我们还发现了研究电致发光器件的一个独特而重要的方面:基于配合物 4c 和 6a 的电致发光器件显示出适度的电致发光效率(EQE = 4.0 和 6.1%),尽管这些配合物在室温下的溶液中没有发射,这表明配合物在溶液中的 PL 特性与电致发光效率没有直接关系。
Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
申请人:Aventis Pharma Deutschland GmbH
公开号:EP1388342A1
公开(公告)日:2004-02-11
The present invention relates to acylated, heteroaryl-condensed cycloalkenylamines of the formula I,
in which A, R1, R2, R3, R4, R5 and n have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds which are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.